Compare LIQT & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIQT | LEXX |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | Denmark | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3M | 22.7M |
| IPO Year | N/A | N/A |
| Metric | LIQT | LEXX |
|---|---|---|
| Price | $1.88 | $1.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $4.20 | $4.00 |
| AVG Volume (30 Days) | 16.3K | ★ 152.2K |
| Earning Date | 11-13-2025 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,788,295.00 | $705,923.00 |
| Revenue This Year | $34.09 | $13.35 |
| Revenue Next Year | $18.75 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 10.97 | ★ 52.05 |
| 52 Week Low | $1.34 | $0.77 |
| 52 Week High | $3.35 | $2.43 |
| Indicator | LIQT | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 40.45 | 71.54 |
| Support Level | $1.81 | $1.05 |
| Resistance Level | $2.14 | $1.17 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 2.47 | 77.27 |
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in three businesses that are diesel particulate filters (DPF) for the control of soot from diesel engines, turnkey ceramic membranes systems, and complete water treatment plants. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and kiln furniture. Its operating segment includes Water, Ceramics, and Plastics.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.